When cancer is caught early, treatment options expand and survival odds improve. But in India, where an estimated 1.5 million new cancer cases are diagnosed each year, the disease is often found at advanced stages, leaving patients with fewer choices and poorer outcomes. A new patent granted to a local biotechnology company aims to change that equation by enabling a blood test that could detect malignancies before symptoms appear and even indicate where in the body the tumor started.
A systems approach to early detection
Strand Life Sciences, a Bengaluru-based firm with a track record in genomics and bioinformatics, received an Indian patent on July 7, 2020, for an integrated platform that analyzes a blood sample for signs of cancer. Unlike conventional tests that look for a single marker, the platform examines patterns of multiple molecular signals — both genetic and epigenetic — and runs them through an algorithm trained to recognize cancer signatures.
The patent covers this integrated, systems-level approach rather than any single biomarker. What researchers found particularly promising is the platform’s ability to predict the tissue of origin — identifying which organ likely harbors the primary tumor. In current practice, if a test simply reports “cancer detected,” the patient still faces an expensive and time-consuming search for the primary site.
Strand’s platform aims to guide that next step, helping doctors decide which organ to investigate further and informing both diagnostic workup and treatment decisions. In Western healthcare systems, patients often have access to PET scans and advanced genetic profiling to locate a primary tumor, but in India those resources are concentrated in major cities.
A blood test that can point to the lung, breast, colon, or pancreas could allow district hospitals to triage patients more effectively and refer them to the right specialist sooner.
Addressing India’s cancer burden
Cancer is a collection of more than 100 diseases characterized by uncontrolled cell growth that can invade or spread to other parts of the body, unlike benign tumors. Many cases arise from genetic changes, some inherited and others caused by environmental factors such as tobacco and alcohol use, poor diet, and lack of exercise. Certain infections from viruses, bacteria, or parasites also contribute, though vaccinations have helped eliminate some of those risks.
Diagnosis typically involves signs, symptoms, or screening tests, followed by medical imaging and biopsy. Treatment often combines surgery, chemotherapy, and radiation therapy, with newer methods such as immunotherapy that harness the patient’s own immune system.
Survival chances depend heavily on the type of cancer and how far it has spread when treatment begins, making early detection a primary goal for improving outcomes. In India, the healthcare infrastructure is stretched, and many patients in rural and semi-urban areas lack access to specialist oncology services. A blood test that is relatively simple to administer, requiring neither expensive imaging equipment nor invasive biopsies for screening, could be deployed widely across the country.
Strand’s patent protects the integrated platform as it moves toward the next phase: clinical validation on larger and more diverse patient populations to confirm accuracy, followed by regulatory approvals and eventual commercialisation. The company has not announced a timeline for those stages; clinical validation in oncology is notoriously slow because false positives and false negatives carry serious consequences.
But the patent gives Strand a protected position from which to build, years of research into circulating tumor DNA and other blood-based markers having laid the groundwork.
The path to clinical adoption
The broader field of liquid biopsy — detecting cancer from a blood sample — has drawn intense global interest, with several companies in the United States and Europe developing similar tests. Strand argues that its patent, covering an integrated platform combining multiple detection methods, gives it a distinctive approach. For patients, the promise is straightforward: a cancer caught early is far more treatable.
The hope is that this technology, once validated and approved, could shift India’s diagnostic landscape from late-stage detection toward earlier intervention. What to watch next is the clinical trial data Strand will need to publish to support its regulatory applications.
The patent is a legal shield, not proof of efficacy; the real test will come when independent researchers and regulators scrutinise the platform’s performance in real-world populations. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Strand Life Sciences secures patent for early cancer detection blood test”, “description”: “BENGALURU, July 7 — When cancer is caught early, treatment options expand and survival odds improve. But in India, where an estimated 1.5 million new…”, “datePublished”: “2026-07-07T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Reza Karimi”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
